Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $13.2 million.

  • Exagen's Operating Expenses rose 1314.84% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.5 million, marking a year-over-year increase of 6460.86%. This contributed to the annual value of $46.7 million for FY2024, which is 1060.37% down from last year.
  • Per Exagen's latest filing, its Operating Expenses stood at $13.2 million for Q3 2025, which was up 1314.84% from $13.0 million recorded in Q2 2025.
  • Exagen's Operating Expenses' 5-year high stood at $27.3 million during Q4 2022, with a 5-year trough of -$4.2 million in Q4 2023.
  • For the 5-year period, Exagen's Operating Expenses averaged around $15.9 million, with its median value being $18.5 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 11529.57% in 2023, then skyrocketed by 38373.21% in 2024.
  • Exagen's Operating Expenses (Quarter) stood at $18.9 million in 2021, then skyrocketed by 44.26% to $27.3 million in 2022, then tumbled by 115.3% to -$4.2 million in 2023, then surged by 383.73% to $11.9 million in 2024, then rose by 11.09% to $13.2 million in 2025.
  • Its Operating Expenses stands at $13.2 million for Q3 2025, versus $13.0 million for Q2 2025 and $12.5 million for Q1 2025.